Live
- Attending Lokayukta a ‘drama’ by Siddaramaiah to escape CBI probe: Pralhad Joshi
- Ola Electric’s share hits all-time low of Rs 74 ahead of Q2 results
- ACME Solar IPO: Concentrated revenue, dependence on govt-owned infra among key risks
- Lalu Prasad Yadav slams Nitish Kumar for his ‘feet touching’ habit
- Pawan Kalyan Criticizes Land Grabs, Calls Police To Act Strict Against anti social elements
- US election day voting begins with first ballots cast in New Hampshire
- Seven 'terrorists' killed in military operations in Pakistan
- Sagility India IPO: Should You Subscribe to This US Healthcare Sector Play?
- India Issues Notices to Wikipedia Over Alleged Bias and False Information
- Kumaraswamy calls FIR against him ridiculous, malicious
Doctor's medical device gets patent
Dr. Nageswara Rao Koneti
A medical device designed and developed by city cardiologist and Director, Rainbow Children’s Heart Institute, Dr. Nageswara Rao Koneti, and his team, to treat Ventricular Septal Defect (VSD), which is a hole between two lower chambers (ventricles) of heart, has received Indian patent
Hyderabad: A medical device designed and developed by city cardiologist and Director, Rainbow Children's Heart Institute, Dr. Nageswara Rao Koneti, and his team, to treat Ventricular Septal Defect (VSD), which is a hole between two lower chambers (ventricles) of heart, has received Indian patent.
Dubbed as KONAR-MF (KOneti NAgeswara Rao- Multi Functional) occlude, the medical device had earlier received European EC approval in 2019 while Euro-African, Korean patents were granted in 2021 and 2022. The Indian patent was granted after several critical examinations in February 2023, a press release said.
Dr. Rao and his team have been working since 2009 to develop the technique and the appropriate occluder for the transcatheter device closure of VSDs. The early results were presented in American college of cardiology meeting at Chicago, USA in 2012.
At present, the device is available commercially through Lifetech Scientific Company, Schengen and has benefitted more than 10,000 patients in last three-years in more than 72 countries including Germany, Italy, UK, USA and Japan, the press release added.
